Giorgio Mosconi
Fondateur chez Acureon Pharmaceuticals, Inc.
Profil
Giorgio Mosconi is the founder of Acureon Pharmaceuticals, Inc. (founded in 2006) and Formula Pharmaceuticals, Inc. (founded in 2009).
He is currently the Chief Strategy Officer at Pierrel Research USA since 2009.
In the past, he held positions as a Director at Pierrel SpA, Principal at Bristol Myers Squibb Co. (from 1996 to 2000), Senior Vice President-Business Development at Vicuron Pharmaceuticals LLC, and VP-Medical Affairs & Business Development at Biosearch Italia SpA.
He also worked as a Principal at Marion Merrell Dow, Inc. Dr. Mosconi obtained a doctorate degree from the University of Georgia in 1989 and another doctorate degree from the University of Milan in 1986.
Postes actifs de Giorgio Mosconi
| Sociétés | Poste | Début |
|---|---|---|
Acureon Pharmaceuticals, Inc.
 Acureon Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Acureon Pharmaceuticals, Inc. develops and markets therapeutics for infectious diseases. The firm’s synergistic combination of anti-infective expertise, dedicated clinical operations, marketing know-how and intellectual property, all coupled with well documented low attrition rates for anti-infective should translate into multiple product opportunities with a lower risk of failure, more rapid development timelines and early substantial returns on investment. The company was founded by Giorgio Mosconi in 2006 and is headquartered in Berwyn, PA. | Fondateur | 23/02/2010 |
| Pierrel Research USA | Corporate Officer/Principal | 01/07/2009 |
Formula Pharmaceuticals, Inc.
 Formula Pharmaceuticals, Inc. Packaged SoftwareTechnology Services Formula Pharmaceuticals, Inc. develops immunotherapies to treat cancer. It offers chimeric antigen receptor technology. The company was founded by Maurits W. Geerlings and Giorgio Mosconi in 2009 and is headquartered in Berwyn, PA. | Fondateur | 01/01/2009 |
Anciens postes connus de Giorgio Mosconi
| Sociétés | Poste | Fin |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2000 |
| PIERREL S.P.A. | Directeur/Membre du Conseil | - |
| Marion Merrell Dow, Inc. | Corporate Officer/Principal | - |
| Biosearch Italia SpA | Directeur Technique/Scientifique/R&D | - |
Vicuron Pharmaceuticals LLC
 Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Corporate Officer/Principal | - |
Formation de Giorgio Mosconi
| University of Georgia | Doctorate Degree |
| University of Milan | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| PIERREL S.P.A. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
Acureon Pharmaceuticals, Inc.
Acureon Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Acureon Pharmaceuticals, Inc. develops and markets therapeutics for infectious diseases. The firm’s synergistic combination of anti-infective expertise, dedicated clinical operations, marketing know-how and intellectual property, all coupled with well documented low attrition rates for anti-infective should translate into multiple product opportunities with a lower risk of failure, more rapid development timelines and early substantial returns on investment. The company was founded by Giorgio Mosconi in 2006 and is headquartered in Berwyn, PA. | Retail Trade |
| Biosearch Italia SpA | Health Technology |
| Marion Merrell Dow, Inc. | Health Technology |
| Pierrel Research USA | |
Formula Pharmaceuticals, Inc.
Formula Pharmaceuticals, Inc. Packaged SoftwareTechnology Services Formula Pharmaceuticals, Inc. develops immunotherapies to treat cancer. It offers chimeric antigen receptor technology. The company was founded by Maurits W. Geerlings and Giorgio Mosconi in 2009 and is headquartered in Berwyn, PA. | Technology Services |
